unlocking the complexity of human immune responses to enable precision immunology

Founded in late 2020, ImmuneID is a precision immunology company that uses its genome-wide, high-throughput platform to provide a comprehensive understanding of individual immune responses. We employ our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease. We were founded by Longwood Fund and are backed by other top-tier venture investors, including Alexandria Venture Investments, Alta Partners, Arch Venture Partners, In-Q-Tel, Pitango, Section 32, Tekla Capital Management and Xfund.

Contact Us

650 East Kendall St, 2nd Floor
Cambridge, MA 02142
info@immuneidrx.com

Stephen Elledge, Ph.D.

Co-founder, ImmuneID

Professor, Medicine, Harvard Medical School
Gregor Mendel Professor of Genetics and of Medicine, Genetics, Harvard Medical School
Professor, Genetics, Brigham And Women’s Hospital

PhD MIT
BS University of Illinois

Steve is widely cited for his many seminal contributions and in particular for his work on the mechanics of both cellular proliferation and the DNA Damage Response. He was awarded the Albert Lasker Prize in Basic Medicine in 2015 for his body of work elucidating how cells sense DNA damage and initiate self-repair. His pioneering research in that field has had a significant impact on understanding human birth defects and aging as well as the genomics of cancer and shows great promise for finding cures. He is also a leader in promoting new genetic technologies and designing methodologies to help researchers better analyze the development of various disorders including cancer, autoimmune diseases and neurodegenerative conditions.

The recipient of numerous other awards including the 2013 Gairdner Foundation international Award, the 2015 Wiley Prize, and the 2017 Gruber Prize in Genetics and the 2017 Breakthrough Prize for Life Sciences for paradigm-shifting research. Dr. Elledge was also a Helen Hay Whitney Fellow, an American Cancer Society Senior Fellow and a Pew Scholar.

Dr. Elledge received his Ph.D. in Biology from the Massachusetts Institute of Technology and his B.S. from the University of Illinois. He completed his post-doctoral studies in the Department of Biochemistry at Stanford University and then joined the faculty of the Baylor College of Medicine in the Department of Biochemistry in 1989 prior to joining Harvard Medical School in 2003.

Elledge’s team is also developing new immunological tools to probe autoimmunity and viral function. One technology they created, called VirScan, detects antibodies against all human viruses in blood. Using a single drop of blood, the method enables researchers to test for current and past viral infections. Others such as T Scan identify the targets of T cells

Elledge’s team recently identified multiple genes that control cell proliferation. The scientists are using this information to reconstruct the higher-order regulatory networks that drive the cell cycle and cancer proliferation. The group has also uncovered many new tumor suppressors and oncogenes by examining the mutational profiles of tumors. They discovered that the distribution of these genes on chromosomes is predictive of the pattern of aneuploidy seen in cancers, providing a new hypothesis of how aneuploidy drives tumorigenesis.

David R. Walt, Ph.D.

Advisor, ImmuneID

Hansjörg Wyss Professor of Biologically Inspired Engineering. Harvard Medical School
Professor of Pathology, Brigham and Women’s Hospital
Institute Professor, Howard Hughes Medical Institute

PhD SUNY Stony Brook
BS University of Michigan

David pioneered the use of microwell arrays for single-molecule detection and analysis, which has revolutionized the process of genetic and proteomic sequencing, enabling the cost of DNA sequencing, and genotyping to plummet nearly a millionfold in the last decade. This technology is now the gold standard for sequencing in a wide variety of applications including screening embryos for genetic defects before in vitro fertilization, studying disease in preserved/frozen tissues, improving crop disease resistance, and identifying individuals’ metabolic profiles to ensure proper drug dosage. David’s current research employs optical fiber microarrays for the detection and analysis of single enzyme molecules to provide mechanistic insight into enzyme mechanisms. In another project, his lab is investigating the limits of creating high-density sensing arrays containing thousands of microsensors and nanosensors and are preparing arrays to perform high-density nucleic acid and protein analysis. One application of this effort is an integrated diagnostic platform for performing medical diagnostics using saliva as a sample instead of blood. The arrays can also be used to study living cells, both as cell populations and as individual cells, and analyze the contents of individual cells by integrating microfluidics with single-molecule detection. They are also studying the behavior of large numbers of cells to understand the distribution of cell behaviors in a population.

David is a member of the faculty at Harvard Medical School in the Department of Pathology, and a Howard Hughes Medical Institute Professor. He is the Scientific Founder of Illumina, Inc. and Quanterix Corp, and has co-founded several other life sciences startups. Previously, he was a University Professor, Professor of Neuroscience, and Professor of Oral Medicine at Tufts University. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He has received numerous awards and honors, including the 2017 American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, the 2016 Ralph Adams Award in Bioanalytical Chemistry, the 2014 American Chemical Society Gustavus John Esselen Award, the 2013 Analytical Chemistry Spectrochemical Analysis Award, the 2013 Pittsburgh Analytical Chemistry Award, and the 2010 ACS National Award for Creative Invention.

Michael Mina, M.D., Ph.D.

SAB, ImmuneID

Assistant Professor, Center for Communicable Disease Dynamics, Department of Epidemiology
Core member, Center for Communicable Disease Dynamics
Assistant Professor in Immunology and Infectious Diseases
Harvard T. H. Chan School of Public Health
Associate Medical Director in Clinical Microbiology (molecular diagnostics) in the Department of Pathology at Brigham and Women’s Hospital, Harvard Medical School

MD/PhD Emory
BA Dartmouth

Dr. Mina earned his MD and PhD degrees from Emory University, with doctoral work split between CDC, St. Jude Children’s Research Hospital, the Respiratory and Meningeal Pathogens Research Unit in Johannesburg, South Africa and the Emory Vaccine Center. He completed his post-doctoral work at Princeton University in Ecology and Evolutionary Biology (of infectious disease dynamics) with Prof. Bryan Grenfell and at Harvard Medical School in the Department of Genetics with Prof. Stephen Elledge. He completed his residency training in clinical pathology at Brigham and Women’s Hospital / Harvard Medical School.

Michael’s research combines mathematical and epidemiological models with high-throughput phage-display based serological laboratory investigations, including development of new technologies and statistical pipelines to better understand the population and immunological consequences and patterns underlying infectious diseases. Much of the work towards new technology development is performed in close collaboration with Steve Elledge at HMS. Major themes of his lab include (i) development of new approaches (laboratory and statistical methods) to enable extremely high-throughput serological surveillance of infectious pathogens; (ii) use of high-complexity antibody profiling and epidemiological data to understand the pathogenesis of vaccine preventable diseases, with a specific focus on measles infections and vaccines; (iii) elucidating broad unintended / heterologous effects of vaccines to alter transmission patterns of unrelated infectious pathogens – using serology and dynamical models; and (iv) understanding the life-history of infectious pathogens across ages, genders, geographies and times. In addition to his interests in infectious diseases, his research also explores more fundamental questions of immunity and immune repertoires: how they form, how they persist, how they are passed on and how they become perturbed during natural life-events.

Kari Nadeau, M.D., Ph.D.

SAB, ImmuneID

Naddisy Foundation Endowed Professor of Medicine and Pediatrics
Section Chief in Asthma and Allergy in the Pulmonary, Allergy and Critical Care Division at Stanford
Sr. Director of Clinical Research for the Division of Hospital Medicine
Director of the Sean N. Parker Center for Allergy and Asthma Research, Stanford University

For more than 30 years, Dr. Nadeau has devoted herself to understanding how environmental and immune/genetic factors affect allergies, immune tolerance, and asthma. She and her team are focused in areas of global climate change and health by studying air pollution and wildfire exposures, particularly in underserved areas. As one of the globe’s foremost experts in adult and pediatric allergy, immunology, and asthma, her research is laying the groundwork for a variety of potential future therapies to prevent and cure allergies and asthma. Dr. Nadeau leads a team of specialists spanning allergy, asthma, and immunology across Stanford University. She has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanism of new therapies and then translating them clinically to make transformative changes for patients and their families. She has led research in oncology, transplant, infectious diseases, COVID, and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH Immune Tolerance Network. She and her team have been awarded many patents and have started 4 biotech companies in the Bay Area under Stanford patents and has worked in industry to shepherd two drugs through the FDA to approval. She also is an author of the Lancet Countdown in Global Climate Change 2020 and the book: The End of Food Allergy (published 2020).

Dr. Nadeau received her MD and PhD from Harvard Medical School through the NIH MSTP program. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in allergy, asthma and immunology at Stanford and at University of California, San Francisco.

Dr. Nadeau has served as an FDA consultant and a reviewer for NIH Study Sections. Also, she served on the environmental health policy committee for the American Thoracic Society and serves on the Data and Safety Monitoring Board (DSMB) of the National Heart, Lung, and Blood Institute (NHLBI), and is a fellow in the American Academy of Allergy, Asthma, and Immunology (AAAAI). She started the Gordon Research Conference for Food Allergy and Chaired the first inaugural conference (2018). She is Chair of the Board of Scientific Counselors for the NIH Clinical Center (2018-2021). She is a member of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the medical board of the American Lung Association in California, the Scientific Advisory Board of the EPA, and is currently working with the US Congress, the WHO, International Wildfire Policy Group, CUGH, and CA Governor’s office on Global Climate Change emergency preparedness plans.

In addition to her above involvements, Dr. Nadeau contributes on multiple editorial boards for high impact journals and to date published over 300 peer-reviewed publications, and is a reviewer for high impact journals in basic science and clinical medicine (Nature, Nature Medicine, Science, Science Translational Medicine, Lancet, NEJM, JAMA, Allergy, JACI).

She is also passionate about breaking down health barriers and creating meaningful change for children and adults in underserved areas and has developed outreach and educational programs with partners in East Palo Alto, Inner City Chicago, Harlem, and San Francisco.

Christoph Westphal, M.D., Ph.D.

Co-founder and Executive Chair, ImmuneID

BA Columbia
MD/PhD Harvard

Dr. Westphal is co-founder and General Partner of Longwood Fund, Chair of ImmuneID, Chair of TScan Therapeutics, Chair of Immunitas Therapeutics, and has spent 20 years as a life sciences CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of six biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $30 billion and have developed and received FDA approval for important drugs. These include: These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), and Verastem (NASDAQ: VSTM). Dr. Westphal is also co- founder of Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly), Axial Biotherapeutics, TScan Therapeutics, Immunitas Therapeutics, Pyxis Oncology and ImmuneID; and co- founder of Concert Pharmaceuticals (NASDAQ: CNCE). Companies founded by Dr. Westphal have created over 6,000 jobs in the Boston area.

Companies founded by Dr. Westphal have developed and received FDA approval for multiple important drugs, including the first RNAi therapy; for currently incurable cancers; the largest-selling heparin in the United States; a therapy for MS; for Beta Thalassemia and Myelodysplastic Syndrome; and several experimental medicines: for cystic fibrosis (phase 3), for serious inflammatory disorders (phase 2), and for serious neurological illnesses such as ALS and MS (positive phase 2).

Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra; he is also in the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles. Dr. Westphal has generally avoided media interviews since 2010.

unlocking the complexity of human immune responses to enable precision immunology

Contact Us

Stephen Elledge, Ph.D.

Co-founder, ImmuneID

Annalisa D’Andrea Ph.D.

President and CSO, ImmuneID

Ben Larman, Ph.D.

Co-founder, ImmuneID

Christopher T. Walsh Ph.D.

Advisor, ImmuneID

David R. Walt, Ph.D.

Advisor, ImmuneID

Michael Mina, M.D., Ph.D.

SAB, ImmuneID

Tomasz Kula, Ph.D.

Co-founder, ImmuneID

Kari Nadeau, M.D., Ph.D.

SAB, ImmuneID

Christoph Westphal, M.D., Ph.D.

Co-founder and Executive Chair, ImmuneID

Lea Hachigian, Ph.D.

Co-founder, ImmuneID

Lucy Liu, Ph.D.

Co-founder, ImmuneID

Thomas Haag, Ph.D. JD

Head of IP, ImmuneID

David H. Donabedian, Ph.D.

CEO, ImmuneID

Ittai Harel

Dan Janney

Steve Kafka, Ph.D.

Jeff Capello

CFO/COO, ImmuneID